CN115851932A - Runx2抑制剂在制备抗乳腺恶性叶状肿瘤药物中的应用 - Google Patents
Runx2抑制剂在制备抗乳腺恶性叶状肿瘤药物中的应用 Download PDFInfo
- Publication number
- CN115851932A CN115851932A CN202211092785.0A CN202211092785A CN115851932A CN 115851932 A CN115851932 A CN 115851932A CN 202211092785 A CN202211092785 A CN 202211092785A CN 115851932 A CN115851932 A CN 115851932A
- Authority
- CN
- China
- Prior art keywords
- runx2
- tumor
- malignant
- breast
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 title claims abstract description 94
- 102000015775 Core Binding Factor Alpha 1 Subunit Human genes 0.000 title claims abstract description 94
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 64
- 230000003211 malignant effect Effects 0.000 title claims abstract description 60
- 210000000481 breast Anatomy 0.000 title claims abstract description 40
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 239000003112 inhibitor Substances 0.000 title claims abstract description 20
- 241001440127 Phyllodes Species 0.000 title abstract description 23
- 238000002360 preparation method Methods 0.000 title description 5
- YSDNWNOGHQYWPK-UHFFFAOYSA-N 2-[(3,4-dichlorophenyl)carbamoyl]bicyclo[2.2.1]hept-5-ene-3-carboxylic acid Chemical compound OC(=O)C1C(C=C2)CC2C1C(=O)NC1=CC=C(Cl)C(Cl)=C1 YSDNWNOGHQYWPK-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229940079593 drug Drugs 0.000 claims abstract description 11
- 238000012216 screening Methods 0.000 claims abstract description 10
- 239000003550 marker Substances 0.000 claims abstract description 5
- 201000011054 breast malignant phyllodes tumor Diseases 0.000 claims description 16
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 239000003596 drug target Substances 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 abstract description 41
- 238000002474 experimental method Methods 0.000 abstract description 35
- 230000014509 gene expression Effects 0.000 abstract description 25
- 230000002018 overexpression Effects 0.000 abstract description 15
- 230000009545 invasion Effects 0.000 abstract description 12
- 230000005012 migration Effects 0.000 abstract description 12
- 238000013508 migration Methods 0.000 abstract description 12
- 150000003384 small molecules Chemical class 0.000 abstract description 11
- 230000004614 tumor growth Effects 0.000 abstract description 11
- 230000035755 proliferation Effects 0.000 abstract description 9
- 238000011161 development Methods 0.000 abstract description 5
- 230000004791 biological behavior Effects 0.000 abstract description 4
- 208000029610 breast phyllodes tumor Diseases 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 3
- 230000009467 reduction Effects 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 238000002626 targeted therapy Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 54
- 230000000694 effects Effects 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 21
- 230000008859 change Effects 0.000 description 12
- 108010035532 Collagen Proteins 0.000 description 11
- 102000008186 Collagen Human genes 0.000 description 11
- 229920001436 collagen Polymers 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 208000026267 malignant phyllodes tumor Diseases 0.000 description 10
- 238000005406 washing Methods 0.000 description 9
- 230000022131 cell cycle Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 238000003197 gene knockdown Methods 0.000 description 7
- 206010027476 Metastases Diseases 0.000 description 6
- 101150086605 Runx2 gene Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000009401 metastasis Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000007789 sealing Methods 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 210000005075 mammary gland Anatomy 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 4
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000004709 cell invasion Effects 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000004017 serum-free culture medium Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 229940126585 therapeutic drug Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 102000016921 Integrin-Binding Sialoprotein Human genes 0.000 description 2
- 108010028750 Integrin-Binding Sialoprotein Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 2
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 2
- 208000002163 Phyllodes Tumor Diseases 0.000 description 2
- 206010071776 Phyllodes tumour Diseases 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000018486 cell cycle phase Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 210000003194 forelimb Anatomy 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 101000741396 Chlamydia muridarum (strain MoPn / Nigg) Probable oxidoreductase TC_0900 Proteins 0.000 description 1
- 101000741399 Chlamydia pneumoniae Probable oxidoreductase CPn_0761/CP_1111/CPj0761/CpB0789 Proteins 0.000 description 1
- 101000741400 Chlamydia trachomatis (strain D/UW-3/Cx) Probable oxidoreductase CT_610 Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000007842 Fibroepithelial Neoplasms Diseases 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 102000008108 Osteoprotegerin Human genes 0.000 description 1
- 108010035042 Osteoprotegerin Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000001046 green dye Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000009818 osteogenic differentiation Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211092785.0A CN115851932A (zh) | 2022-09-08 | 2022-09-08 | Runx2抑制剂在制备抗乳腺恶性叶状肿瘤药物中的应用 |
| PCT/CN2022/118895 WO2024050861A1 (fr) | 2022-09-08 | 2022-09-15 | Utilisation d'un inhibiteur de runx2 dans la préparation d'un médicament de lutte contre des tumeurs phyllodes malignes du sein |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211092785.0A CN115851932A (zh) | 2022-09-08 | 2022-09-08 | Runx2抑制剂在制备抗乳腺恶性叶状肿瘤药物中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115851932A true CN115851932A (zh) | 2023-03-28 |
Family
ID=85660812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211092785.0A Pending CN115851932A (zh) | 2022-09-08 | 2022-09-08 | Runx2抑制剂在制备抗乳腺恶性叶状肿瘤药物中的应用 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN115851932A (fr) |
| WO (1) | WO2024050861A1 (fr) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3271327A4 (fr) * | 2015-03-19 | 2018-11-21 | University of Maryland, Baltimore | Inhibiteurs du facteur de transcription runx2 et utilisations associées |
| GB201820994D0 (en) * | 2018-12-21 | 2019-02-06 | Uea Enterprises Ltd | Methods of treatment and diagnosis of tumours |
| WO2021048292A1 (fr) * | 2019-09-11 | 2021-03-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes et compositions pour le traitement d'un mélanome |
-
2022
- 2022-09-08 CN CN202211092785.0A patent/CN115851932A/zh active Pending
- 2022-09-15 WO PCT/CN2022/118895 patent/WO2024050861A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024050861A1 (fr) | 2024-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yang et al. | RETRACTED: Exosome-derived miR-130a activates angiogenesis in gastric cancer by targeting C-MYB in vascular endothelial cells | |
| WO2021088119A1 (fr) | Milieu de culture de cellules épithéliales mammaires primaires, son procédé de culture et son utilisation | |
| Zhang et al. | MNX1 is oncogenically upregulated in African-American prostate cancer | |
| Wang et al. | Relation between the expression of mitotic centromere–associated kinesin and the progression of squamous cell carcinoma of the tongue | |
| Matsumura et al. | Oncogenic property of acrogranin in human uterine leiomyosarcoma: direct evidence of genetic contribution in in vivo tumorigenesis | |
| CN111979290B (zh) | Spp1基因在制备增强卵巢癌患者对parp抑制剂敏感性的药物中的应用 | |
| Zhai et al. | Analysis of clinical factors and PDGFR-β in predicting prognosis of patients with clival chordoma | |
| Wang et al. | Expression and prognostic impact of PRL‐3 in lymph node metastasis of gastric cancer: its molecular mechanism was investigated using artificial microRNA interference | |
| Yang et al. | Repression of bone morphogenetic protein 4 by let-7i attenuates mesenchymal migration of head and neck cancer cells | |
| CN114042072B (zh) | Stm2457的新用途 | |
| Li et al. | Upregulated LINC01088 facilitates malignant phenotypes and immune escape of colorectal cancer by regulating microRNAs/G3BP1/PD-L1 axis | |
| KR101593049B1 (ko) | 3차원 콜라겐 겔 환경에서 라이실-ｔＲＮＡ 합성효소가 발현하거나 발현하지 않도록 조절된 세포 또는 회전타원체로 덩어리진 세포 배양을 이용한 암 전이 억제제의 스크리닝 방법 | |
| CN108660212B (zh) | Wdr1基因在制备非小细胞肺癌治疗和检测产品中的应用 | |
| Lee et al. | A functionally robust phenotypic screen that identifies drug resistance-associated genes using 3D cell culture | |
| CN111387143A (zh) | miRNA-203a-3p在开发抑制胰腺癌药物中的应用 | |
| CN113929764B (zh) | 一种乳腺叶状肿瘤分子标志物cd146及其应用 | |
| CN115851932A (zh) | Runx2抑制剂在制备抗乳腺恶性叶状肿瘤药物中的应用 | |
| CN113862361B (zh) | 一种诊断和治疗膀胱癌的分子标志物hsf1及其用途 | |
| Zheng et al. | Mechanism for bioactive nanomaterial circ0024831 regulation of staphylococcal nuclease domain containing 1 via RNA methylation recognition in osteosarcoma | |
| Chang et al. | Isolation of a human gallbladder cancer cell clone with high invasive phenotype in vitro and metastatic potential in orthotopic model and inhibition of its invasiveness by heparanase antisense oligodeoxynucleotides | |
| CN113855663A (zh) | 冬凌草甲素在制备抗***癌药物中的用途 | |
| CN107893119B (zh) | Zcchc12在骨肉瘤中的应用 | |
| CN107881240B (zh) | 骨肉瘤的诊治标志物 | |
| WO2024050860A1 (fr) | Réactif de diagnostic pour tumeur phyllode et son utilisation | |
| Moss et al. | FAU regulates carboplatin resistance in ovarian cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |